Which marker could be elevated in nonmalignant liver disease?

Which marker could be elevated in nonmalignant liver disease?

• A. AFP
• B. CEA
• C. CA 15-3
• D. All of the above

Answer: (D)

Some tumor markers aren’t cancer-specific and can rise with benign liver conditions. Alpha-fetoprotein is produced mainly during fetal development, but in adults it can increase with liver injury and regeneration, such as in hepatitis or cirrhosis, so modest elevations don’t necessarily mean cancer. Carcinoembryonic antigen is cleared by the liver, and liver disease—especially with inflammation or cholestasis—can cause small rises as well. CA 15-3, tied to mucin-1, can also be elevated in benign hepatobiliary disease and liver dysfunction, not just in breast cancer. Because each marker can be influenced by nonmalignant liver processes, they all could be elevated in nonmalignant liver disease. Context from imaging and clinical findings is essential to interpret these markers accurately.

Some tumor markers aren’t cancer-specific and can rise with benign liver conditions. Alpha-fetoprotein is produced mainly during fetal development, but in adults it can increase with liver injury and regeneration, such as in hepatitis or cirrhosis, so modest elevations don’t necessarily mean cancer. Carcinoembryonic antigen is cleared by the liver, and liver disease—especially with inflammation or cholestasis—can cause small rises as well. CA 15-3, tied to mucin-1, can also be elevated in benign hepatobiliary disease and liver dysfunction, not just in breast cancer. Because each marker can be influenced by nonmalignant liver processes, they all could be elevated in nonmalignant liver disease. Context from imaging and clinical findings is essential to interpret these markers accurately.